Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk

2007 ◽  
Vol 16 (1) ◽  
pp. 13-19 ◽  
Author(s):  
Michael A. Weber ◽  
George L. Bakris ◽  
Björn Dahlöf ◽  
Bertram Pitt ◽  
Eric Velazquez ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Combination Therapy ◽  
Cardiovascular Events ◽  
Systolic Hypertension ◽  
High Cardiovascular Risk ◽  
Hypertensive Population ◽  
Baseline Characteristics

scholarly journals Prognostic value of myocardial perfusion scintigraphy in asymptomatic patients with diabetes mellitus at high cardiovascular risk: 5-year follow-up of the prospective multicenter BARDOT trial

2021 ◽  
Author(s):  
Federico Caobelli ◽  
◽  
Philip Haaf ◽  
Gianluca Haenny ◽  
Matthias Pfisterer ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Myocardial Perfusion ◽  
Cardiovascular Events ◽  
Prognostic Value ◽  
Myocardial Perfusion Scintigraphy ◽  
Major Adverse Cardiovascular Events ◽  
Diabetic Patients ◽  
Perfusion Scintigraphy ◽  
High Cardiovascular Risk

Abstract Background The Basel Asymptomatic High-Risk Diabetics’ Outcome Trial (BARDOT) demonstrated that asymptomatic diabetic patients with an abnormal myocardial perfusion scintigraphy (MPS) were at increased risk of major adverse cardiovascular events (MACEs) at 2-year follow-up. It remains unclear whether this finding holds true even for a longer follow-up. Methods Four hundred patients with type 2 diabetes, neither history nor symptoms of coronary artery disease (CAD), were evaluated clinically and with MPS. Patients were followed up for 5 years. Major adverse cardiovascular events (MACEs) were defined as all-cause death, myocardial infarction, or late coronary revascularization. Results At baseline, an abnormal MPS (SSS ≥ 4 or SDS ≥ 2) was found in 87 of 400 patients (22%). MACE within 5 years occurred in 14 patients with abnormal MPS (16.1%) and in 22 with normal scan (1.7%), p = 0.009; 15 deaths were recorded. Patients with completely normal MPS (SSS and SDS = 0) had lower rates of MACEs than patients with abnormal scans (2.5% vs. 7.0%, p = 0.032). Patients with abnormal MPS who had undergone revascularization had a lower mortality rate and a better event-free survival from MI and revascularization than patients with abnormal MPS who had either undergone medical therapy only or could not be revascularized (p = 0.002). Conclusions MPS may have prognostic value in asymptomatic diabetic patients at high cardiovascular risk over a follow-up period of 5 years. Patients with completely normal MPS have a low event rate and may not need retesting within 5 years. Patients with an abnormal MPS have higher event rates and may benefit from a combined medical and revascularization approach.

Real-World Characteristics And Risk Of Cardiovascular Events In High Cardiovascular Risk Patients In France

2019 ◽  
Vol 287 ◽  
pp. e180
Author(s):  
G. Désaméricq ◽  
F. Fagnani ◽  
C. Emery ◽  
J. Gourmelen ◽  
J.V. Chauny ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Real World ◽  
Cardiovascular Events ◽  
High Cardiovascular Risk ◽  
Risk Patients

scholarly journals The use of angiotensin receptor blocker losartan in the combinational therapy of arterial hypertension

2009 ◽  
Vol 6 (4) ◽  
pp. 12-15
Author(s):  
N Sh Zagidullin ◽  
Sh Z Zagidullin
Keyword(s):  
Cardiovascular Risk ◽  
Combination Therapy ◽  
Arterial Hypertension ◽  
Resistant Hypertension ◽  
Angiotensin Receptor Blocker ◽  
High Efficiency ◽  
Combined Therapy ◽  
Angiotensin Receptor ◽  
High Cardiovascular Risk ◽  
Combinational Therapy

Blockade of renin-angiotensin systems is one problem in the treatment of arterial hypertension. Resistant hypertension and patients with high cardiovascular risk demand frequently use of combination therapy. The efficiency of combined therapy losartan plus hydrochlorothiazide at patients with arterial hypertension was studied in several large clinical multicentre randomized studies. It is proved high efficiency and safety of this combination therapy.

Sign in / Sign up

Export Citation Format

Share Document